Medications for opioid use disorder in the Department of Veterans Affairs (VA) health care system: Historical perspective, lessons learned, and next steps

References

• Gordon AJ, Trafton JA, Saxon AJ, et al; and Buprenorphine Work Group of the Substance Use Disorders Quality Enhancement Research Initiative. Implementation of buprenorphine in the Veterans Health Administration: Results of the first 3 years. Drug Alcohol Depend. 2007;90(2):292–296.
   PubMed Web of Science ®Google Scholar
• VA Mental Health Information System, Measure Components Summary BETA. https://spsites.cdw.va.gov/sites/OMHO_MHMP/_layouts/15/ReportServer/RSViewerPage.aspx?rv%3aRelativeReportUrl =/sites/OMHO_MHMP/AnalyticsReports/MHIS/MHISSummary.rdl. Accessed January 4, 2018.
   Google Scholar
• Bohnert, A. S., Ilgen, M. A., Galea, S., McCarthy, J. F., & Blow, F. C. (2011). Accidental poisoning mortality among patients in the Department of Veterans Affairs Health System. Medical care, 49(4), 393–396.
   PubMed Web of Science ®Google Scholar
• Bohnert, A. S., Valenstein, M., Bair, M. J., Ganoczy, D., McCarthy, J. F., Ilgen, M. A., & Blow, F. C. (2011). Association between opioid prescribing patterns and opioid overdose-related deaths. Jama, 305(13), 1315–1321.
   PubMed Web of Science ®Google Scholar
• Hadlandsmyth, K., Mosher, H., Vander Weg, M. W., & Lund, B. C. (2018). Decline in Prescription Opioids Attributable to Decreases in Long-Term Use: A Retrospective Study in the Veterans Health Administration 2010–2016. Journal of general internal medicine, 1–7.
   PubMed Web of Science ®Google Scholar
• Lin, L. A., Bohnert, A. S., Kerns, R. D., Clay, M. A., Ganoczy, D., & Ilgen, M. A. (2017). Impact of the opioid safety initiative on opioid-related prescribing in veterans. Pain, 158(5), 833–839.
   PubMed Web of Science ®Google Scholar
• Fiellin DA, Pantalon MV, Chawarski MC, et al. Counseling plus buprenorphine–naloxone maintenance therapy for opioid dependence. N Engl J M. 2006;355(4):365–374.
   PubMed Web of Science ®Google Scholar
• Marsch LA. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta‐analysis. Addiction. 1998;93(4):515–532.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;3(3).
   Google Scholar
• Veterans Health Administration. About VHA. https://www.va.gov/health/aboutVHA.asp. Accessed January 22, 2018.
   Google Scholar
• Cantor JM. The alcohol and drug dependence program of the Veterans Administration. J Drug Issues. 1974;4(1):44–51.
   Web of Science ®Google Scholar
• Cranston A. Legislative approaches to addiction among Veterans: the nation's unmet moral responsibility. J Drug Issues. 1974;4(1):1–10.
   Web of Science ®Google Scholar
• Oliva EM, Harris AH, Trafton JA, Gordon AJ. Receipt of opioid agonist treatment in the Veterans Health Administration: Facility and patient factors. Drug Alcohol Depend. 2012;122(3):241–246.
   PubMed Web of Science ®Google Scholar
• VA Office of Inspector General. Independent Review of VA's Fiscal Year 2011 Detailed Accounting Summary Report to the Office of National Drug Control Policy. Washington, DC: US Dept of Veterans Affairs; 2012.
   Google Scholar
• U.S. Department of Veterans Affairs. Pharmacy Benefits Management Services. https://www.pbm.va.gov. December 17, 2017. Accessed January 22, 2018.
   Google Scholar
• Oliva EM, Trafton JA, Harris AH, Gordon AJ. Trends in opioid agonist therapy in the Veterans Health Administration: Is supply keeping up with demand?. Am J Drug Alcohol Abuse. 2013;39(2):103–107.
   PubMed Web of Science ®Google Scholar
• Rubinsky AD, Chen C, Batki SL, Williams EC, Harris AH. Comparative utilization of pharmacotherapy for alcohol use disorder and other psychiatric disorders among US Veterans Health Administration patients with dual diagnoses. J Psychiatr Res. 2015;69:150–157.
   PubMed Web of Science ®Google Scholar
• Gordon AJ, Liberto J, Granda S, Salmon-Cox S, Andrée T, McNicholas L. Outcomes of DATA 2000 certification trainings for the provision of buprenorphine treatment in the Veterans Health Administration. Am J Addict. 2008;17(6):459–462.
   PubMed Web of Science ®Google Scholar
• Gellad WF, Good CB, Shulkin DJ. Addressing the Opioid Epidemic in the United States: Lessons From the Department of Veterans Affairs. JAMA Intern Med. 2017;177(5):611–612.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Veterans Affairs. Pharmacy Benefits Management Services. About Us. https://www.pbm.va.gov/PBM/academicdetailingservice/AboutUs.asp. October 30, 2017. Accessed January 22, 2018.
   Google Scholar
• Gordon AJ, Kavanagh G, Krumm M, et al. Facilitators and barriers in implementing buprenorphine in the Veterans Health Administration. Psychol Addict Behav. 2011;25(2):215.
   PubMed Web of Science ®Google Scholar
• Veterans Health Administration. Uniform Mental Health Services in VA Medical Centers and Clinics in VHA Handbook 1160.01. Washington, DC: US Dept of Veterans Affairs; 2008.
   Google Scholar
• US Department of Veterans Affairs and US Department of Defense. VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders. Version 2.0. Washington, DC: US Dept of Veterans Affairs and US Dept of Defense; 2009.
   Google Scholar
• US Department of Veterans Affairs and US Department of Defense. VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders. Version 3.0. Washington, DC: US Dept of Veterans Affairs and US Dept of Defense; 2015.
   Google Scholar
• Finlay AK, Harris AH, Rosenthal J, et al. Receipt of pharmacotherapy for opioid use disorder by justice-involved US Veterans Health Administration patients. Drug Alcohol Depend. 2016;160:222–226.
   PubMed Web of Science ®Google Scholar
• US Department of Veterans Affairs and US Department of Defense. VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders. Version 3.0. Washington, DC: US Dept of Veterans Affairs and US Dept of Defense; 2015.
   Google Scholar
• Oliva EM, Maisel NC, Gordon AJ, Harris AH. Barriers to use of pharmacotherapy for addiction disorders and how to overcome them. Curr Psychiatry Rep. 2011;13(5):374.
   PubMed Web of Science ®Google Scholar
• Manhapra A, Quinones L, Rosenheck R. Characteristics of veterans receiving buprenorphine vs. methadone for opioid use disorder nationally in the Veterans Health Administration. Drug Alcohol Depend. 2016;160:82–89.
   PubMed Web of Science ®Google Scholar
• Manhapra A, Petrakis I, Rosenheck R. Three‐year retention in buprenorphine treatment for opioid use disorder nationally in the Veterans Health Administration. Am J Addict. 2017;26(6):572–580.
   PubMed Web of Science ®Google Scholar
• Zubkoff L, Shiner B, Watts BV. Staff Perceptions of Substance Use Disorder Treatment in VA Primary Care–Mental Health Integrated Clinics. J Subst Abuse Treat. 2016;70:44–49.
   PubMed Web of Science ®Google Scholar
• Harris AH, Ellerbe L, Reeder RN, et al. Pharmacotherapy for alcohol dependence: Perceived treatment barriers and action strategies among Veterans Health Administration service providers. Psychol Serv. 2013; 10(4): 410–19.
   PubMed Web of Science ®Google Scholar
• Williams EC., Achtmeyer CE, Young JP, et al. Barriers to and facilitators of alcohol use disorder pharmacotherapy in primary care: a qualitative study in five VA clinics. J Gen Intern Med 2017; 1–10.
   Web of Science ®Google Scholar
• Harris, AH, Brown R., Dawes, M. Effects of a multifaceted implementation intervention to increase utilization of pharmacological treatments for alcohol use disorders in the US Veterans Health Administration. J Subst Abuse Treat. 2017; 82:107–112.
   PubMed Web of Science ®Google Scholar
• Korthuis PT, McCarty D, Weimer M, et al. Primary Care–Based Models for the Treatment of Opioid Use Disorder: A Scoping Review. Ann Intern Med. 2016;166(4):268–278.
   PubMed Web of Science ®Google Scholar
• Santa Ana EJ, Stallings DL, Rounsaville BJ, Martino S. Development of an in-home telehealth program for outpatient veterans with substance use disorders. Psychol Serv. 2013;10(3):304.
   PubMed Web of Science ®Google Scholar
• Ruskin, P. E., Silver-Aylaian, M., Kling, M. A., Reed, S. A., Bradham, D. D., Hebel, J. R., … & Hauser, P. (2004). Treatment outcomes in depression: comparison of remote treatment through telepsychiatry to in-person treatment. American Journal of Psychiatry, 161(8), 1471–1476.
   PubMed Web of Science ®Google Scholar
• Fortney, J. C., Pyne, J. M., Edlund, M. J., Williams, D. K., Robinson, D. E., Mittal, D., & Henderson, K. L. (2007). A randomized trial of telemedicine-based collaborative care for depression. Journal of General Internal Medicine, 22(8), 1086–1093.
   PubMed Web of Science ®Google Scholar
• S-524 Comprehensive Addiction and Recovery Act. (Accessed Nov 22, 2016 at https://www.congress.gov/bill/114th-congress/senate-bill/524/text).
   Google Scholar
• Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS): 2016. Data on Substance Abuse Treatment Facilities. BHSIS Series S-93, HHS Publication No. (SMA) 17–5039. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2017.
   Google Scholar